Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Bowering

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Canadian Journal of Diabetes|September 28, 2013
Foot care, Keith Bowering, John M Embil
Diabetes Care|February 22, 2018
Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957Bruce W Bode, Keith Bowering, David Russell-Jones
Canadian Journal of Diabetes|April 14, 2018
Foot Care, John M Embil, Zaina Albalawi, et al.
Diabetes Care|January 17, 2015
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trialStephan Matthaei, Keith Bowering, Katja Rohwedder, et al.
Diabetes, Obesity & Metabolism|March 30, 2019
Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetesAnne L Peters, Milivoj Piletič, Johan Ejstrud, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|July 3, 2004
MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessmentDavid H Keast, C Keith Bowering, A Wayne Evans, et al.
Diabetes Care|May 10, 2017
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 TrialKeith Bowering, Christopher Case, John Harvey, et al.
Annals of Internal Medicine|October 19, 2005
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trialJulio Rosenstock, Bernard Zinman, Liam J Murphy, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 15, 2018
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc AnalysisKeith Bowering, Helena W Rodbard, David Russell-Jones, et al.
Canadian Journal of Diabetes|September 28, 2013
Type 2 diabetes mellitus management in Canada: is it improving?Lawrence A Leiter, Lori Berard, C Keith Bowering, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Canadian Journal of Diabetes|September 28, 2013
Foot care, Keith Bowering, John M Embil
Diabetes Care|February 22, 2018
Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957Bruce W Bode, Keith Bowering, David Russell-Jones
Canadian Journal of Diabetes|April 14, 2018
Foot Care, John M Embil, Zaina Albalawi, et al.
Diabetes Care|January 17, 2015
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trialStephan Matthaei, Keith Bowering, Katja Rohwedder, et al.
Diabetes, Obesity & Metabolism|March 30, 2019
Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetesAnne L Peters, Milivoj Piletič, Johan Ejstrud, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|July 3, 2004
MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessmentDavid H Keast, C Keith Bowering, A Wayne Evans, et al.
Diabetes Care|May 10, 2017
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 TrialKeith Bowering, Christopher Case, John Harvey, et al.
Annals of Internal Medicine|October 19, 2005
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trialJulio Rosenstock, Bernard Zinman, Liam J Murphy, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 15, 2018
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc AnalysisKeith Bowering, Helena W Rodbard, David Russell-Jones, et al.
Canadian Journal of Diabetes|September 28, 2013
Type 2 diabetes mellitus management in Canada: is it improving?Lawrence A Leiter, Lori Berard, C Keith Bowering, et al.
Pageof 1